Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels

Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management

(2013) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma

(2013) S Maïga et al.   BRITISH JOURNAL OF CANCER

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

(2013) Daniel Heintel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma

(2013) G Srivastava et al.   LEUKEMIA

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

(2012) S. Kumar et al.   BLOOD

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

(2012) A Lopez-Girona et al.   LEUKEMIA

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

(2012) Yuan Xiao Zhu et al.   LEUKEMIA & LYMPHOMA

Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management

(2011) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

A review of the history, properties, and use of the immunomodulatory compound lenalidomide

(2011) Jerome B. Zeldis et al.   Annals of the New York Academy of Sciences

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications

(2011) J. Jakubikova et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

(2011) Antonia Lopez-Girona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects

(2011) Nianhang Chen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Treatment of multiple myeloma

(2011) S. Vincent Rajkumar   Nature Reviews Clinical Oncology

Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors

(2010) Charlotte Chaulet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

(2010) F. van Rhee et al.   BLOOD

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo

(2010) Zhengzi Qian et al.   LEUKEMIA RESEARCH

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

IRF4: Immunity. Malignancy! Therapy?

(2009) A. L. Shaffer et al.   CLINICAL CANCER RESEARCH

Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2

(2008) B. K. Arendt et al.   BLOOD

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE